Earnings

EBIT and EBITDA

Following the severe impact of the coronavirus pandemic in the prior-year period when earnings before interest and tax (EBIT) totaled just €272.8 million, EBIT in the first nine months of 2021 reached €623.9 million, reflecting the widespread recovery of the market. EBIT included budgeted negative effects from purchase price allocations totaling €63.1 million (Q1–Q3 2020: €66.4 million). There were also non-recurring items amounting to a total expense of €4.1 million in the reporting period. The prior-year figure, an expense of €24.6 million, mainly included adverse effects on earnings from the capacity and structural program as well as an impairment charge on an equity investment. EBIT adjusted for non-recurring items and purchase price allocation effects (adjusted EBIT) amounted to €691.1 million in the first nine months of the year (Q1–Q3 2020: €363.8 million). The adjusted EBIT margin improved to 9.2 percent (Q1–Q3 2020: 6.1 percent).

EBIT

in € million

Q3
2021

Q3
2020

Q1 – Q3
2021

in % of revenue

Q1 – Q3
2020

in % of revenue

EBITDA

209.1

135.2

623.9

8.3%

272.8

4.5%

Adjustment by functional costs:

 

 

 

 

 

 

+ Cost of sales

9.5

14.8

28.4

0.4%

35.1

0.6%

+ Selling expenses and administrative expenses

13.0

11.5

42.5

0.6%

47.2

0.8%

+ Research and development costs

0.0

0.0

0.1

0.0%

0.2

0.0%

+ Other costs

–2.8

–2.4

–3.9

–0.1%

8.6

0.1%

Adjusted EBITDA

228.9

159.1

691.1

9.2%

363.8

6.1%

adjusted for non-recurring items

–1.4

2.2

4.1

0.1%

24.6

0.4%

adjusted for PPA items

21.2

21.6

63.1

0.8%

66.4

1.1%

Earnings before interest, tax, depreciation, and amortization (EBITDA) rose to €1,317.6 million (Q1–Q3 2020: €962.1 million). Adjusted EBITDA increased to €1,321.4 million (Q1–Q3 2020: €986.7 million), giving an adjusted EBITDA margin of 17.5 percent (Q1–Q3 2020: 16.4 percent).

EBITDA

in € million

Q3
2021

Q3
2020

Q1 – Q3
2021

in % of revenue

Q1 – Q3
2020

in % of revenue

EBITDA

443.7

365.0

1,317.6

17.5%

962.1

16.0%

Adjustment by functional costs:

 

 

 

 

 

 

+ Cost of sales

0.0

4.8

0.0

0.0%

4.8

0.1%

+ Selling expenses and administrative expenses

1.4

–0.2

8.0

0.1%

11.2

0.2%

+ Research and development costs

0.0

0.0

0.0

0.0%

0.0

0.0%

+ Other costs

–3.2

–2.4

–4.2

–0.1%

8.6

0.1%

Adjusted EBITDA

441.9

367.3

1,321.4

17.5%

986.7

16.4%

adjusted for non-recurring items

–1.9

2.2

3.8

0.0%

24.6

0.4%

adjusted for PPA items

0.0

0.0

0.0

0.0%

0.0

0.0%

EBITDA for the long-term leasing business, which is derived from internal reporting and assumes a minimum rate of return on the capital employed, amounted to €248.8 million in the reporting period (Q1–Q3 2020: €248.6 million).